437 related articles for article (PubMed ID: 28384752)
1. Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis.
Lunetta C; Lizio A; Maestri E; Sansone VA; Mora G; Miller RG; Appel SH; Chiò A
JAMA Neurol; 2017 Jun; 74(6):660-667. PubMed ID: 28384752
[TBL] [Abstract][Full Text] [Related]
2. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study.
Chiò A; Calvo A; Bovio G; Canosa A; Bertuzzo D; Galmozzi F; Cugnasco P; Clerico M; De Mercanti S; Bersano E; Cammarosano S; Ilardi A; Manera U; Moglia C; Sideri R; Marinou K; Bottacchi E; Pisano F; Cantello R; Mazzini L; Mora G;
JAMA Neurol; 2014 Sep; 71(9):1134-42. PubMed ID: 25048026
[TBL] [Abstract][Full Text] [Related]
3. Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre-specified and post hoc analyses.
Miller RG; Zhang R; Bracci PM; Azhir A; Barohn R; Bedlack R; Benatar M; Berry JD; Cudkowicz M; Kasarskis EJ; Mitsumoto H; Manousakis G; Walk D; Oskarsson B; Shefner J; McGrath MS
Muscle Nerve; 2022 Jul; 66(1):39-49. PubMed ID: 35098554
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.
Miller RG; Block G; Katz JS; Barohn RJ; Gopalakrishnan V; Cudkowicz M; Zhang JR; McGrath MS; Ludington E; Appel SH; Azhir A;
Neurol Neuroimmunol Neuroinflamm; 2015 Jun; 2(3):e100. PubMed ID: 25884010
[TBL] [Abstract][Full Text] [Related]
5. NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study.
Miller RG; Zhang R; Block G; Katz J; Barohn R; Kasarskis E; Forshew D; Gopalakrishnan V; McGrath MS
Amyotroph Lateral Scler Frontotemporal Degener; 2014 Dec; 15(7-8):601-9. PubMed ID: 25192333
[TBL] [Abstract][Full Text] [Related]
6. Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trial.
Bowser R; An J; Mehta L; Chen J; Timmons J; Cudkowicz M; Paganoni S
J Neurol Neurosurg Psychiatry; 2024 Jun; 95(7):605-608. PubMed ID: 38050066
[TBL] [Abstract][Full Text] [Related]
7. Adipokines, C-reactive protein and Amyotrophic Lateral Sclerosis - results from a population- based ALS registry in Germany.
Nagel G; Peter RS; Rosenbohm A; Koenig W; Dupuis L; Rothenbacher D; Ludolph AC
Sci Rep; 2017 Jun; 7(1):4374. PubMed ID: 28663573
[TBL] [Abstract][Full Text] [Related]
8. Association of Serum Retinol-Binding Protein 4 Concentration With Risk for and Prognosis of Amyotrophic Lateral Sclerosis.
Rosenbohm A; Nagel G; Peter RS; Brehme T; Koenig W; Dupuis L; Rothenbacher D; Ludolph AC;
JAMA Neurol; 2018 May; 75(5):600-607. PubMed ID: 29482216
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein levels in patients with amyotrophic lateral sclerosis: A systematic review.
Kharel S; Ojha R; Preethish-Kumar V; Bhagat R
Brain Behav; 2022 Mar; 12(3):e2532. PubMed ID: 35201675
[TBL] [Abstract][Full Text] [Related]
10. Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression.
Murdock BJ; Zhou T; Kashlan SR; Little RJ; Goutman SA; Feldman EL
JAMA Neurol; 2017 Dec; 74(12):1446-1454. PubMed ID: 28973548
[TBL] [Abstract][Full Text] [Related]
11. Biological follow-up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis.
Patin F; Corcia P; Madji Hounoum B; Veyrat-Durebex C; Respaud E; Piver E; Benz-de Bretagne I; Vourc'h P; Andres CR; Blasco H
Eur J Neurol; 2015 Oct; 22(10):1385-90. PubMed ID: 26095828
[TBL] [Abstract][Full Text] [Related]
12. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis.
Su XW; Simmons Z; Mitchell RM; Kong L; Stephens HE; Connor JR
JAMA Neurol; 2013 Dec; 70(12):1505-11. PubMed ID: 24145899
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis.
Boylan KB; Glass JD; Crook JE; Yang C; Thomas CS; Desaro P; Johnston A; Overstreet K; Kelly C; Polak M; Shaw G
J Neurol Neurosurg Psychiatry; 2013 Apr; 84(4):467-72. PubMed ID: 23117489
[TBL] [Abstract][Full Text] [Related]
14. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort.
Mariosa D; Hammar N; Malmström H; Ingre C; Jungner I; Ye W; Fang F; Walldius G
Ann Neurol; 2017 May; 81(5):718-728. PubMed ID: 28437840
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the Innate Immune System as a Therapeutic Approach to Supporting Respiratory Function in ALS.
McGrath MS; Zhang R; Bracci PM; Azhir A; Forrest BD
Cells; 2023 Mar; 12(7):. PubMed ID: 37048104
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Meininger V; Genge A; van den Berg LH; Robberecht W; Ludolph A; Chio A; Kim SH; Leigh PN; Kiernan MC; Shefner JM; Desnuelle C; Morrison KE; Petri S; Boswell D; Temple J; Mohindra R; Davies M; Bullman J; Rees P; Lavrov A;
Lancet Neurol; 2017 Mar; 16(3):208-216. PubMed ID: 28139349
[TBL] [Abstract][Full Text] [Related]
17. Blood biomarkers and prognosis of amyotrophic lateral sclerosis.
Sun J; Carrero JJ; Zagai U; Evans M; Ingre C; Pawitan Y; Fang F
Eur J Neurol; 2020 Nov; 27(11):2125-2133. PubMed ID: 32557963
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients.
Milligan C; Atassi N; Babu S; Barohn RJ; Caress JB; Cudkowicz ME; Evora A; Hawkins GA; Wosiski-Kuhn M; Macklin EA; Shefner JM; Simmons Z; Bowser RP; Ladha SS
Muscle Nerve; 2021 Sep; 64(3):309-320. PubMed ID: 34075589
[TBL] [Abstract][Full Text] [Related]
19. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
[TBL] [Abstract][Full Text] [Related]
20. Macrophage-Targeted Sodium Chlorite (NP001) Slows Progression of Amyotrophic Lateral Sclerosis (ALS) through Regulation of Microbial Translocation.
Zhang R; Bracci PM; Azhir A; Forrest BD; McGrath MS
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36428474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
